

07/27/04

1624



Shw/B
CASE 4-30972A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 540154162 US
Express Mail Label Number

July 26 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

BRAIN ET AL.

Examiner: T. McKenzie

APPLICATION NO: 10/009,009

FILED: DECEMBER 20, 2001

FOR: BRADYKININ RECEPTOR ANTAGONISTS

Attention: Janet Higgins

U.S. Patent and Trademark Office
2231 Crystal Drive
Suite 910
Arlington, VA 22202

COMMUNICATION


Sir:

As per our discussion by telephone today to supply you with legible copies of pages 10 and 11 of this application, enclosed are replacement pages 10 and 11 for your records.

Please do not hesitate to call if you have further questions.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370
(862) 778-7960

Date: July 26, 2004

Compound	R ^{3A}	m	n	R ^{6A}
5.23	5-methylisoxazol-3-ylmethyl	2	0	-CH ₃
5.24	2-methylthiazol-4-ylmethyl	2	0	-CH ₃
5.25	-CH ₂ CHC(CH ₃) ₂	2	0	-CH ₃
5.26	-CH ₂ CHCHCH ₃	2	0	-CH ₃
5.27	-CH ₂ C ₆ H ₁₁	2	0	-CH ₃
5.28	-CH ₂ C ₄ H ₇	2	0	-CH ₃
5.29	-CH ₂ CCCH ₃	2	0	-CH ₃
5.30	thiophen-3-ylmethyl	2	0	-CH ₃
5.31	thiophen-2-ylmethyl	2	0	-CH ₃
5.32	-CH ₂ CCCH ₂ CH ₃	2	0	-CH ₃
5.33	-CH(CH ₃) ₂	2	0	-CH ₃

CHARACTERISING DATA

Compounds of the above tables are found to exhibit the following HPLC retention data [min]:


No.	[min]	No.	[min]	No.	[min]	No.	[min]
1	5.91*	1.5	7.17****	26	24.95***	5.15	6.083*
2	5.68*	1.6	5.0*****	27	5.90*	5.16	6.100*
3	6.22*	1.7	5.7*****	28	6.23*	5.17	6.067*
4	5.43**	16	24.03***	29	5.35*	5.18	5.967*
5	23.55***	17	4.6****	30	5.75*	5.19	4.767*
6	5.24**	18	20.1***	5.1	5.833*	5.20	4.667*
7	25.93***	19	22.6***	5.2	6.367*	5.21	5.567*
8	5.09**	20	22.58***	5.3	6.100*	5.22	6.02*
9	23.98***	21	27.57***	5.4	6.250*	5.23	6.138*
10	23.89***	22	22.9***	5.5	6.167*	5.24	6.087*
11	6.37*	3.1	5.03*****	5.6	6.45*	5.25	6.558*
12	23.68***	3.2	5.8*	5.7	6.200*	5.26	6.382*
13	5.10**	3.3	5.83*	5.8	5.467	5.27	6.932*
14	6.17****	3.4	3.4*****	5.9	6.167*	5.28	6.547*
15	5.28****	4.1	5.467*	5.10	5.900*	5.29	6.26*
1.1	4.95*****	4.2	5.822*	5.11	6.338*	5.30	6.453*

No.	[min]	No.	[min]	No.	[min]	No.	[min]
1.2	6.00****	23	5.57*	5.12	6.998*	5.31	5.7*****
1.3	6.4****	24	5.9*	5.13	6.983*	5.32	5.7*****
1.4	6.82****	25	23.82***	5.14	7.03*	5.33	6.510*

HPLC conditions:

- *: Hypersil 3 micron C 18 BDS column. Gradient elution 10-100% MeCN in water (+0.1% TFA) over 10 min
- ** : Kingsorb 50x4.6mm C18 column, 3micron particle size; flow rate 3ml/min; 90% water (+10mM NH₄OAc 0.3% HCOOH) 10% MeCN to 100% MeCN over 10min
- ***: Nucleosil 5 micron C18 column, 25cm x 4.6mm. Gradient elution 10-100% MeCN in water (+0.1% TFA) over 40 min
- ****: Waters Symmetry 3 micron C18 column; 5 x 0.46 cm. Gradient elution, 10% to 100% MeCN in water (+ 0.1% TFA) over 10 min
- *****: Kingsorb 3 micron C18 column, 30x4.6mm, gradient elution 10 % MeCN in water (+0.1% TFA) to 100% MeCN over 10 min

Compounds of formula IIA wherein X¹, R⁹ and R¹⁰ have the above meanings and X² is a divalent group of formula



wherein R^{1A} and R^{2A} independently are C₁-C₄alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring,
may be prepared applying known techniques, e.g. in accordance with the following reaction scheme: